The pharmaceutical industry stands at a critical juncture. Traditional drug discovery processes are notoriously inefficient, with the Tufts Center for the Study of Drug Development reporting an average cost of $1–2 billion and a timeline of 10–15 years to bring a single new active substance to market. A significant portion of these exorbitant costs stems...
At Pharmatech AI, we are proud to announce our strategic partnership with QuantifAI, an institutional-grade quant-trading platform combining advanced AI with blockchain’s transparency. As experts in AI-powered drug discovery, focusing on nanomedicine, pain therapy, natural products, and cannabinoid research, we are committed to pushing the boundaries of pharmaceutical innovation. This collaboration with QuantifAI enhances our...
At Pharmatech AI, we are proud to announce our strategic partnership with Wag3s, a leading Web3 platform for AI-driven accounting, crypto tax, and HR management. As experts in AI-powered drug discovery, focusing on nanomedicine, pain therapy, natural products, and cannabinoid research, we are committed to pushing the boundaries of pharmaceutical innovation. This collaboration with Wag3s...
At Pharmatech AI, we are excited to announce our strategic partnership with Router Protocol, a cutting-edge Layer-1 blockchain enabling chain abstraction and seamless ecosystem connectivity. As leaders in AI-driven drug discovery, specializing in nanomedicine, pain therapy, natural products, and cannabinoid research, we are dedicated to advancing innovative therapies through state-of-the-art technology. This collaboration with Router...
At Pharmatech AI, we are excited to announce our strategic partnership with Tenzor Assets, a leader in leveraging AI and mathematical models to evaluate intangible assets and manage financial risks across industries. As pioneers in AI-driven drug discovery, focusing on nanomedicine, pain therapy, natural products, and cannabinoid research, we are dedicated to accelerating innovative therapies....
At Pharmatech AI, we are thrilled to announce our strategic partnership with the International Intelligent Innovation Computing Center (IIICC). As a leading company in AI-driven drug discovery, specializing in nanomedicine, pain therapy, natural products, and cannabinoid research, we are committed to leveraging cutting-edge technologies to develop innovative therapies. This collaboration with IIICC, a pioneer in...
We at Pharmatech AI are proud to announce that we have secured a $5 million strategic investment from Rollman Management, a renowned investment firm with a focus on groundbreaking technologies. This partnership underscores the confidence in our mission to revolutionize pharmaceutical research through artificial intelligence and blockchain technology. This investment will enable us to further...
Germany, July 15, 2025 – Pharmatech AI has entered into a strategic collaboration with Deutsche Anbaugesellschaft DAG GmbH, marking a significant advancement in cannabinoid-based therapy development through artificial intelligence. This partnership combines Pharmatech AI’s cutting-edge AI technologies with DAG’s extensive expertise in cannabis cultivation and processing to create a powerful synergy in pharmaceutical research. Through...
Mary Jane Berlin 2025 proved once again why it’s Europe’s premier cannabis networking event – and our team, including our CEO, was at the heart of the action. As a research-driven company specializing in cannabis-derived active compounds and cannabinoids, events like these are crucial for building the partnerships that drive our work forward. Why Networking...
We’re excited to announce that Pharmatech AI will be attending Mary Jane Berlin 2025, World’s largest and most influential cannabis trade fair! Join us as we explore groundbreaking opportunities in cannabinoid research and AI-driven drug discovery. Meet Our Team: Our CEO and other core team members will be available for exclusive B2B meetings to discuss:...